Tirzepatide
- Generic Name
- Tirzepatide
- Brand Names
- Mounjaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2023788-19-2
- Unique Ingredient Identifier
- OYN3CCI6QE
- Background
Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclini...
- Indication
Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 54
- Registration Number
- NCT04050670
- Locations
- 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 475
- Registration Number
- NCT04039503
- Locations
- 🇩🇪
Schwerpunktpraxis Diabetes, Saint Ingbert-Oberwürzbach, Saarland, Germany
🇯🇵Tokyo Center Clinic, Chuo-ku, Tokyo, Japan
🇺🇸Sun Coast Clinical Research, Inc, New Port Richey, Florida, United States
A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT04004988
- Locations
- 🇸🇬
Lilly Nus Centre for Clin Pharmacology, Singapore, Singapore
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1879
- Registration Number
- NCT03987919
- Locations
- 🇺🇸
PharmQuest, Greensboro, North Carolina, United States
🇺🇸Aventiv Research Inc, Columbus, Ohio, United States
🇺🇸Biopharma Informatic, Inc., Houston, Texas, United States
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
- First Posted Date
- 2019-05-17
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 478
- Registration Number
- NCT03954834
- Locations
- 🇮🇳
BSES Municipal General Hsptl, Mumbai, Maharashtra, India
🇯🇵Meiwa Hospital, Chiyodaku, Tokyo, Japan
🇯🇵Tokyo Center Clinic, Chuo-ku, Tokyo, Japan
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 117
- Registration Number
- NCT03951753
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
🇩🇪Profil Mainz GmbH & Co. KG, Mainz, Rheinland-Pfalz, Germany
A Study of Tirzepatide in Participants With Impaired Liver Function
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT03940742
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸New Orleans Center for Clinical Research, New Orleans, Louisiana, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1444
- Registration Number
- NCT03882970
- Locations
- 🇺🇸
Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸National Research Institute, Panorama City, California, United States
🇺🇸Catalina Research Institute, LLC, Montclair, California, United States
A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 636
- Registration Number
- NCT03861052
- Locations
- 🇯🇵
Medical Corporation Chiseikai Tokyo Center Clinic, Chuo-ku, Tokyo, Japan
🇯🇵Ikebukuro Metropolitan Clinic, Toshima-ku, Tokyo, Japan
🇯🇵IHL Shinagawa East One Medical Clinic, Minato-ku, Tokyo, Japan
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 443
- Registration Number
- NCT03861039
- Locations
- 🇯🇵
Yuri Ono Clinic, Sapporo, Hokkaido, Japan
🇯🇵Miyanomori Hospital, Sapporo, Hokkaido, Japan
🇯🇵Ikeda Hospital, Amagasaki, Hyogo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.